PDS Biotech: 84.4% 36-month OS in cervical cancer trial of Versamune HPV + chemoradiation

PDS Biotechnology Corp

36-month OS rate 84.4% (all patients) vs ~64% historical; 100% in 8 patients receiving all 5 doses.
36-month PFS rate 74.9% overall, 100% in fully dosed subgroup; historical ~61%.
Complete metabolic response (CMR) in 88% (15/17) of patients at 4 months per PET.
Versamune HPV well-tolerated; most common related AE injection site reaction (71%).
Median follow-up 19 months; data presented at ASTRO 2024, awarded Basic/Translational Science Award.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.